Cardiovascular pharmacogenomics and individualized drug therapy

被引：50
|
作者：
Pereira, Naveen L. [1 ]
Weinshilboum, Richard M. [2 ]
机构：
[1] Mayo Clin, Div Cardiovasc Dis, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Div Clin Pharmacol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA
来源：
NATURE REVIEWS CARDIOLOGY | 2009年 / 6卷 / 10期
关键词：
CONGESTIVE-HEART-FAILURE; CYP2D LOCUS; WARFARIN; POLYMORPHISMS; ASSOCIATION; METABOLISM; GENE; IDENTIFICATION; DEBRISOQUINE; INFORMATION;
D O I：
10.1038/nrcardio.2009.154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The goal of individualized drug therapy requires physicians to be able to accurately predict an individual's response to a drug. Both genetic and environmental factors are known to influence drug response. 'Pharmacogenetics' is the study of the role of inheritance in variation in drug response phenotypes. Pharmacogenetics is now moving genome-wide to become 'pharmacogenomics', resulting in the recognition of novel biomarkers for individual variation in drug response. This article reviews the development, promise and challenges facing pharmacogenomics, using examples of drugs used to treat or prevent cardiovascular disease.
引用
收藏
页码：632 / 638
页数：7
相关论文
共 50 条
  • [1] Cardiovascular pharmacogenomics and individualized drug therapy
    Naveen L. Pereira
    Richard M. Weinshilboum
    [J]. Nature Reviews Cardiology, 2009, 6 : 632 - 638
  • [2] Pharmacogenomics and individualized drug therapy
    Eichelbaum, M
    Ingelman-Sundberg, M
    Evans, WE
    [J]. ANNUAL REVIEW OF MEDICINE, 2006, 57 : 119 - 137
  • [3] Pharmacogenomics: towards individualized drug therapy
    Eichelbaum, M.
    [J]. FEBS JOURNAL, 2006, 273 : 26 - 26
  • [4] Pharmacogenomics:: The quest for individualized therapy
    López-López, M
    Guerrero-Camacho, JL
    Familiar-López, IM
    Jung-Cook, H
    Corona-Vázquez, T
    Alonso-Vilatela, ME
    [J]. REVISTA DE NEUROLOGIA, 2004, 39 (11) : 1063 - 1071
  • [5] Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead
    Nebert, DW
    Vesell, ES
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 500 (1-3) : 267 - 280
  • [6] Pharmacogenomics and adverse drug reactions in cardiovascular drug therapy.
    Taber, SS
    Welage, LS
    Leady, MA
    Streetman, DS
    [J]. PHARMACOTHERAPY, 2003, 23 (10): : 1358 - 1358
  • [7] Pharmacogenomics in schizophrenia: the quest for individualized therapy
    Basile, VS
    Masellis, M
    Potkin, SG
    Kennedy, JL
    [J]. HUMAN MOLECULAR GENETICS, 2002, 11 (20) : 2517 - 2530
  • [8] Pharmacogenomics of microRNA: a miRSNP towards individualized therapy
    Bertino, Joseph R.
    Banerjee, Debabrata
    Mishra, Prasun J.
    [J]. PHARMACOGENOMICS, 2007, 8 (12) : 1625 - 1627
  • [9] Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy
    Weng, Liming
    Zhang, Li
    Peng, Yan
    Huang, R. Stephanie
    [J]. PHARMACOGENOMICS, 2013, 14 (03) : 315 - 324
  • [10] Pharmacogenomics of methotrexate: moving towards individualized therapy
    Nersting, Jacob
    Schmiegelow, Kjeld
    [J]. PHARMACOGENOMICS, 2009, 10 (12) : 1887 - 1889
12345